Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma: We Need Your Help!
Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) for an upcoming drug review on:
Ledaga (also referred to as Valchlor) for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL).
If you have MF-CTCL and have received this treatment, you can help by completing our survey. If you have MF-CTCL but have not received this treatment, you can still complete this survey and will be redirected to questions only about your lymphoma.
The survey provides us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will close at midnight Pacific Time on Monday, January 11, and should only take between 15-20 minutes of your time.
You may access the survey by clicking the button below:
Please share and help us spread the word.
Thank you for your support.